TABLE 10.

Clinical trials with vintafolide in ovarian cancer.

Name of the study	Year of the study	Phase of the study	Research group	Dose of vintafolide	Results
Lorusso et al. (LoRusso et al., 2012)	2012	I	32	2.5 mg intravenously on days 1, 3, and 5 and days 15, 17, and 19 of each 28-day cycle	Acceptable safety profile; 1 (out of 4) patient with ovarian cancer had partial response to treatment
PRECEDENT (Naumann et al., 2013)	2013	II	162, (vintafolide plus doxorubicin group n = 109, doxorubicin alone group n = 53)	2.5 mg intravenously 3 times per week during weeks 1 and 3	Vintafolide plus doxorubicin group, doxorubicin alone group: PFS 5.0, 2.7 months, respectively

PFS, progression-free survival.